Navigation Links
Results From Investigator-Sponsored Trials Presented at SSIEM Conference
Date:9/1/2010

a >20% reduction in phenylalanine levels and also showed improved activation for a region in the orbitomedial PFC.

Pilot study to evaluate the effects of Kuvan on adult individuals with Phenylketonuria with measurable maladaptive behaviors (Moseley, et al; University of Southern California/Keck School of Medicine): Preliminary six-month data in ten subjects with measurable maladaptive behaviors showed that while there was a small decrease in blood Phe concentrations there was a large decrease in the Phe/Tyr ratio. Additionally, improvements were measured in all negative behaviors, most specifically, irritability and rage.

About KuvanKuvan® (sapropterin dihydrochloride) Tablets are indicated in the United States to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet. The active ingredient in Kuvan, sapropterin dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe. Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Kuvan has received seven years of orphan exclusivity in the United States and ten years of market exclusivity in the E.U.

Important Safety Information

Prolonged exposure to elevated blood Phe levels in PKU patients can result in severe neurologic damage. The initiation of KUVAN therapy does not eliminate the need for careful monitoring of blood Phe levels and ongoing dietary management.

Some patients receiving Kuvan can experience significant drops in blood Phe levels. Patients should be monitored closely to ensure that blood Phe levels do not fall too low.

Not all patients with PKU respond to treatment with Kuvan.
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Proprietary Zinc/Phytase Formulation Improved Botulinum Toxin A Results
2. Accuray Announces Results for Fourth Quarter and Fiscal Year 2010
3. CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
4. Unilife Corporation Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2010
5. Cyberonics Reports Strong Fiscal 2011 First Quarter Results
6. Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging
7. Topline Results From Phase 3 Trial of Sunitinib With Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC)
8. MedClean Technologies Announces Second Quarter Results
9. Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results
10. Huifeng Bio-Pharmaceutical Reported Second Quarter 2010 Financial Results and Reaffirms its 2010 Guidance
11. China Yongxin Pharmaceuticals Reports Second Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... the development and sale of patented biopharmaceutical medicine, modernized ... ingredients (API) today announced the business and development progress ... 1. Following the September 2014 JCM application (No. ...
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
(Date:1/22/2015)... (NASDAQ: AMGN ) today announced that it will report ... Jan. 27, 2015, after the close of the U.S. financial markets. ... investment community at 2 p.m. PT. Participating in the call from ... executive officer, and other members of Amgen,s senior management team. ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... - Once-daily TMC278, the third anti-HIV compound to be developed ... ... YARDLEY, Pa., July 17 Tibotec Pharmaceuticals Ltd.,announced today ... non-nucleoside reverse transcriptase inhibitor (NNRTI),in treatment-naive adults with HIV-1, are ...
... Anesiva,Inc. (Nasdaq: ANSV ) today announced that it ... company,s long-acting, site specific, non-opioid,drug candidate for the management ... rotator cuff repair., Adlea is currently in two ... knee replacement surgeries and one in bunionectomy surgeries. An,additional ...
Cached Medicine Technology:Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV 2Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV 3Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery 2Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery 3Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery 4
(Date:1/23/2015)... Hastings and Hastings, a law firm in Arizona that ... legal representation client review requests for slip and fall accidents ... in the number of slip and fall related accidents that ... With that said, a large number of injury victims are ... firm. Hastings and Hastings is a personal injury firm in ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 The U.S. ... R.Ph., DICVP, Director of Clinical Pharmacy Services at North ... the recipient of the 2015 Beal Award for Distinguished ... USP has relied on the contributions of volunteer experts ...
(Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
(Date:1/22/2015)... 2015 Woodloch Pines, an all-inclusive family ... by TripAdvisor as the number one best large hotel for ... the world for their annual Travelers’ Choice Awards. , ... The website is home to millions of unbiased and honest ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3
... on State,Children,s Health Insurance Program (SCHIP), WASHINGTON, ... Thanksgiving break with a clear conscience before it ... by passing an adequately,funded SCHIP bill," said Dr. ... Alliance for Hispanic Health, the nation,s leading Hispanic ...
... is most likely to experience osteoarthritis, and to test whether ... their sights on people who sustain a knee injury, seeking ... on to develop osteoarthritis, a debilitating condition that causes pain ... , The work is funded by a special class ...
... C. Benjamin, MD, FACP, FACEP (E) Executive ... 18 The following statement,by Georges C. Benjamin, ... Health Association., "The American Public Health Association ... of Representatives to uphold the intent of the,overwhelming ...
... 18 Medical Decisions Network,(MDN) announces Food and ... Insulin Dosing Software. The MDN-CGS software is used,by ... dosage of,intravenous insulin administered to patients with elevated ... the body converts to energy for survival. ...
... old age linked to mental woes, study finds , THURSDAY, ... may boost the risk of dementia later in life, U.S. ... analyzed the dental records and annual cognitive test results of ... an examination of aging and Alzheimer,s disease among sisters of ...
... the,leading global provider of dosage form solutions, announced ... have now been licensed by,eight of the top ... Licaps(R) Drug Delivery System, these companies are using ... stage,development and manufacturing of Phase 1 clinical trial ...
Cached Medicine News:Health News:What's been causing your knee to ache? Smurfs! 2Health News:What's been causing your knee to ache? Smurfs! 3Health News:Nation's Children are the Only Losers in Failure to Override CHIP Veto 2Health News:FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software 2Health News:Capsugel's Liquid Dosage Form Technology Utilized by Eight of the Top 10 Pharmaceutical Companies 2
... Insulin-like growth factor I (IGF-I or somatomedin C) ... the liver. It acts as a potent mitogen ... to specific cell-surface receptors. In the circulation, IGF-I ... to regulate the actions of IGF-I by modulating ...
... 5a-Dihydrotestosterone (DHT) is a potent ... through the action of cholestenone 5a-reductase ... are highest in certain peripheral tissues, ... and are localized intra-cellularly in apparent ...
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
... in two modelsthe BT4, which offers four ... offers five. With the simple push of ... your needs. Both models come fully-equipped ... ankle/foot supports, adjustable arm boards, patient restraints, ...
Medicine Products: